Halozyme (NASDAQ:HALO) stock surged after 2025 guidance upgrade and a Morgan Stanley rating boost. Read more here.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2025, provided an update on its recent ...

Halozyme Therapeutics Inc (HALO) reports a 41% revenue increase, raises 2025 guidance, and advances share repurchase program ...

Halozyme Therapeutics HALO reported second-quarter 2025 adjusted earnings of $1.54 per share, which comprehensively beat the ...

Q2 2025 Management View CEO Helen I. Torley opened the call stating, "I'm pleased to announce another record quarter, which highlights the significant growth and accelerating momentum we have across ...

Halozyme Therapeutics (NASDAQ:HALO) reported non-GAAP earnings per share (EPS) of $1.54, beating non-GAAP estimates by $0.30 and growing 69% year over year (non-GAAP). Revenue (GAAP) was $325.7 ...

Analysts expect Halozyme Therapeutics to report an earnings per share (EPS) of $1.20. Anticipation surrounds Halozyme ...

News provided by Halozyme Therapeutics, Inc. Jan 08, 2025, 7:00 AM ET Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance Raises 2025 Financial Guidance ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported second-quarter net income of $165.2 million. On a per-share basis, the San Diego-based company said it had ...

SAN DIEGO, July 12, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval ...

Halozyme Therapeutics Inc is bolstering its drug delivery platform with a $960 million all-cash deal for specialty pharmaceutical company Antares Pharma Inc , the companies said on Wednesday.